Show simple item record

dc.contributor.authorCortés, José R.
dc.contributor.authorSánchez-Díaz, Raquel
dc.contributor.authorBovolenta, Elena R.
dc.contributor.authorBarreiro, Olga
dc.contributor.authorLasarte, Sandra
dc.contributor.authorMatesanz-Marín, Adela
dc.contributor.authorToribio, María L.
dc.contributor.authorSánchez Madrid, Francisco 
dc.contributor.authorMartín, Pilar
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.date.accessioned2015-05-27T10:18:03Z
dc.date.available2015-05-27T10:18:03Z
dc.date.issued2015-01-01
dc.identifier.citationJournal of Autoimmunity 55 (2014): 51-62en_US
dc.identifier.issn0896-8411 (print)en_US
dc.identifier.issn1095-9157 (online)en_US
dc.identifier.urihttp://hdl.handle.net/10486/666421
dc.description.abstractAlthough FoxP3+ regulatory T cells are key players in the maintenance of immune tolerance and autoimmunity, the lack of specific markers constitute an obstacle to their use for immunotherapy protocols. In this study, we have investigated the role of the C-type lectin receptor CD69 in the suppressor function of Tregs and maintenance of immune tolerance towards harmless inhaled antigens. We identified a novel FoxP3+CD69+ Treg subset capable to maintain immune tolerance and protect to developing inflammation. Although CD69+ and CD69−FoxP3+ Tregs exist in homeostasis, only CD69-expressing Tregs express high levels of CTLA-4, ICOS, CD38 and GITR suppression-associated markers, secrete high amounts of TGFβ and have potent suppressor activity. This activity is regulated by STAT5 and ERK signaling pathways and is impaired by antibody-mediated down-regulation of CD69 expression. Moreover, immunotherapy with FoxP3+CD69+ Tregs restores the homeostasis in Cd69−/− mice, that fail to induce tolerance, and is also highly proficient in the prevention of inflammation. The identification of the FoxP3+CD69+ Treg subset paves the way toward the development of new therapeutic strategies to control immune homeostasis and autoimmunityes_ES
dc.description.sponsorshipThis work was supported by funding from the Spanish Ministry of Economy and Competitiveness: SAF2011-27330 to P.M., SAF2010-15106 to M.L.T and SAF2011-25834 to F.S-M.; grant INDISNET (S2010/BMD-2332) from Comunidad de Madrid and RETICS Enfermedades Cardiovasculares (RD12/0042/0056) from Instituto de Salud Carlos III to P.M and F. S-M; and ERC-2011-AdG294340-GENTRIS to F.S-M. J.R.C. was supported by a CNIC post-doctoral fellowship, R. S-D is funded with a pre-doctoral fellowship from Comunidad de Madrid and E.R.B. and A.M-M. were supported by a FPI pre-doctoral fellowship from the Spanish Ministry of Economy and Competitiveness. The CNIC is supported by the Spanish Ministry of Economy and Competitiveness and the Pro CNIC Foundationen_US
dc.format.extent28 pag.en
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Autoimmunityen_US
dc.rights© 2014, Elsevieren_US
dc.subject.otherCD69es_ES
dc.subject.otherFoxP3es_ES
dc.subject.otherImmune toleranceen_US
dc.subject.otherRegulatory T cellsen_US
dc.titleMaintenance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expressionen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.date.embargoend2015-12-01
dc.identifier.publicationfirstpage51es_ES
dc.identifier.publicationissue1es_ES
dc.identifier.publicationlastpage62es_ES
dc.identifier.publicationvolume55es_ES
dc.relation.projectIDComunidad de Madrid. S2010/BMD-2332/INDISNETes_ES
dc.type.versioninfo:eu-repo/semantics/acceptedVersionen
dc.rights.ccReconocimiento – NoComercial – SinObraDerivadaes_Es
dc.rights.accessRightsopenAccessen
dc.authorUAMSánchez Madrid, Francisco (259404)
dc.facultadUAMFacultad de Medicina


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record